Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - GALECTIN THERAPEUTICS INC | d16270d8k.htm |
Exhibit 16.1
September 9, 2015
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read Galectin Therapeutics, Inc.’s statements included under Item 4.01 of its Form 8-K to be filed on September 11, 2015 and we agree with such statements concerning our firm.
/s/ McGladrey LLP
McGladrey LLP